Eton Pharmaceuticals says first patient dosed in study of ET-700

Eton Pharmaceuticals (ETON) announced the first patient has been dosed in a pilot clinical study assessing the efficacy of ET-700, the company’s proprietary, patent-pending formulation of extended-release zinc acetate under development for the treatment of Wilson disease. Topline study results are expected in the second half of 2026, and if positive, would lead to a pivotal clinical study in early 2027.”ET-700 has the potential to deliver a major advancement for patients with Wilson disease, and we’re excited to initiate this clinical study. Based on feedback from the patient community and treating physicians, there remains a meaningful need for more convenient, simpler dosing approaches for this lifelong chronic therapy, which ET-700 is designed to explore. If approved, we believe ET-700 could exceed $100 million of peak annual sales in the United States,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.